14282-64-5

Basic information

• Product Name: 5-Hydroxymethyl-2-thiophene carbocylic acid
• Synonyms: 5-Hydroxymethyl-2-thiophene carbocylic acid;5-Hydroxymethyl-2-thiophenecarboxylic acid
• CAS NO: 14282-64-5
• Molecular Formula: C₆H₆O₃S
• Molecular Weight: 158.17504
• Mol File: 14282-64-5.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 5-Hydroxymethyl-2-thiophene carbocylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Hydroxymethyl-2-thiophene carbocylic acid(14282-64-5)
• EPA Substance Registry System: 5-Hydroxymethyl-2-thiophene carbocylic acid(14282-64-5)

Safety Data

• Hazardous Substances Data: 14282-64-5(Hazardous Substances Data)

Upstream product

• 4565-31-5 5-formyl-2-thiophencarboxylic acid 
• 530145-16-5 5-hydroxymethyl-2-thiophenecarboxylic acid methyl ester 

Downstream Products

• 527-72-0 2-thiophenylcarboxylic acid 

Relevant articles and documents

Metal-Free Aerobic Oxidative Selective C-C Bond Cleavage in Heteroaryl-Containing Primary and Secondary Alcohols

A transition-metal-free aerobic oxidative selective C-C bond-cleavage reaction in primary and secondary heteroaryl alcohols is reported. This reaction was highly efficient and tolerated various heteroaryl alcohols, generating a carboxylic acid derivative and a neutral heteroaromatic compound. Experimental studies combined with density functional theory calculations revealed the mechanism underlying the selective C-C bond cleavage. This strategy also provides an alternative simple approach to carboxylation reaction.

MONOCYCLIC PYRIDINE DERIVATIVE

The present invention provides a novel compound having FGFR inhibitory activity or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing the same. Specifically, the present invention provides a compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof: wherein n represents 0 to 2; A represents an arylene group or a heteroarylene group; G represents a single bond, an oxygen atom or —CH2—; E represents a nitrogen-containing non-aromatic heterocycle; R1 represents an alkoxy group or the like; R2 represents a hydrogen atom or the like; and R3 represents a hydrogen atom, an alkyl group, an alkoxy group or the like, with the proviso that when E represents an azetidine ring and R2 or R3 is present on a nitrogen atom on the azetidine ring, the R2 or R3 does not represent a hydrogen atom.

TRICYCLIC DERIVATIVES OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, THEIR PREPARATIONS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

The present invention relates to tricyclic derivatives or pharmaceutically acceptable salts thereof, their preparations and pharmaceutical compositions containing them. More precisely, the present invention relates to tricyclic derivatives as colchicine derivatives, pharmaceutically acceptable salts thereof, their preparations and pharmaceutical compositions containing them. Tricyclic derivatives of the present invention show very powerful cytotoxicity to cancer cell lines but were much less toxic than colchicine or taxol, confirmed through animal toxicity test. Tricyclic derivatives of the invention also decrease the volume and weight of a tumor and have a strong angiogenesis inhibiting activity in HUVEC cells. Thus, tricyclic derivatives of the present invention can effectively be used as an anticancer agent, anti-proliferation agent and an angiogenesis inhibitor.